Gastroenterology

Gastroenterology

Volume 124, Issue 6, May 2003, Pages 1662-1671
Gastroenterology

Postinfectious irritable bowel syndrome1

https://doi.org/10.1016/S0016-5085(03)00324-XGet rights and content

Abstract

A small but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of their IBS symptoms after a bout of gastroenteritis. Population-based surveys show that although a history of neurotic and psychologic disorders, pain-related diseases, and gastroenteritis are all risk factors for developing IBS, gastroenteritis is the most potent. More toxigenic organisms increase the risk 11-fold, as does an initial illness lasting more than 3 weeks. Hypochondriasis and adverse life events double the risk for postinfective (PI)-IBS and may account for the increased proportion of women who develop this syndrome. PI-IBS is associated with modest increases in mucosal T lymphocytes and serotonin-containing enteroendocrine cells. Animal models and some preliminary human data suggest this leads to excessive serotonin release from the mucosa. Both the histologic changes and symptoms in humans may last for many years with only 40% recovering over a 6-year follow-up. Celiac disease, microscopic colitis, lactose intolerance, early stage Crohn’s disease, and bile salt malabsorption should be excluded, as should colon cancer in those over the age of 45 years or in those with a positive family history. Treatment with Loperamide, low-fiber diets, and bile salt- binding therapy may help some patients. Serotonin antagonists are logical treatments but have yet to be evaluated.

Section snippets

Epidemiology

One of the earliest reports of PI-IBS relates to unexplained diarrhea and abdominal discomfort seen in British troops returning from the World War II North Africa campaign after amebic dysentery.5 The term postdysenteric irritable bowel syndrome was first used by Chaudhary and Truelove,6 who described 130 cases of “irritable colon syndrome,” 34 of whom dated the onset of their symptoms to an attack of either bacillary or amebic dysentery. This retrospective survey suggested that such patients

References (72)

  • C.M. Prather et al.

    Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

    Gastroenterology

    (2000)
  • M.J. Camilleri et al.

    Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS)

    Gastroenterology

    (2000)
  • R. Mossner et al.

    Role of serotonin in the immune system and in neuroimmune interactions

    Brain Behav Immun

    (1998)
  • R. Lisker et al.

    Intestinal lactase deficiency and milk drinking capacity in the adult

    Am J Clin Nutr

    (1978)
  • S. Miehlke et al.

    Budesonide treatment for collagenous colitisa randomized, double-blind, placebo-controlled, multicenter trial

    Gastroenterology

    (2002)
  • M. Pimentel et al.

    Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

    Am J Gastroenterol

    (2000)
  • D.S. Sanders et al.

    Association of adult coeliac disease with irritable bowel syndromea case-control study in patients fulfilling ROME II criteria referred to secondary care

    Lancet

    (2001)
  • K.R. Palmer et al.

    Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea

    Gastroenterology

    (1980)
  • M. Riberdy-Poitras et al.

    Amitriptylin for the treatment of IBS

    Gastroenterology

    (2000)
  • T.S. King et al.

    Abnormal colonic fermentation in irritable bowel syndrome

    Lancet

    (1998)
  • M.A. O’Sullivan et al.

    Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study

    Dig Liver Dis

    (2000)
  • S. Nobaek et al.

    Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

    Am J Gastroenterol

    (2000)
  • K.D. Fine et al.

    Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis

    Gastroenterology

    (1998)
  • M.W. McKendrick

    Post Salmonella irritable bowel syndrome-5-year review

    J Infect

    (1996)
  • R.F. Harvey et al.

    Prognosis in the irritable bowel syndromea 5-year prospective study

    Lancet

    (1987)
  • R. Boulton-Jones et al.

    Significance of anxiety in IBS outpatientsrelation to bowel symptoms and final diagnosis

    Gut

    (2002)
  • W.G. Thompson et al.

    Functional bowel disorders and functional abdominal pain

    Gut

    (1999)
  • S.P. Dunlop et al.

    Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS

    Gastroenterology

    (2002)
  • G.T. Stewart

    Post-dysenteric colitis

    Br Med J

    (1950)
  • N.A. Chaudhary et al.

    The irritable colon syndrome

    QJM

    (1962)
  • K.A. Gwee et al.

    The role of psychological and biological factors in postinfective gut dysfunction

    Gut

    (1999)
  • K.R. Neal et al.

    Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndromepostal survey of patients

    BMJ

    (1997)
  • J.P. Thornley et al.

    Relationship of campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome

    J Infect Dis

    (2001)
  • S.D. Parry et al.

    Does infectious diarrhoea (ID) predispose people to functional gastro-intestinal disorders (FGIDs)? A prospective community case-control study

    Gut

    (2002)
  • L.A. Rodriguez et al.

    Increased risk of irritable bowel syndrome after bacterial gastroenteritiscohort study

    BMJ

    (1999)
  • J.G. Wheeler et al.

    Study of infectious intestinal disease in Englandrates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive

    Br Med J

    (1999)
  • Cited by (0)

    1

    Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective.

    View full text